Synmosa Biopharma Corporation (TPEX:4114)
Taiwan
· Delayed Price · Currency is TWD 30.80
-0.95 (-2.99%)
Mar 9, 2026, 1:30 PM CST
Synmosa Biopharma Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 15,445 | 14,499 | 14,706 | 16,021 | 7,016 | 6,814 | Upgrade
|
| Market Cap Growth | 8.26% | -1.41% | -8.21% | 128.36% | 2.96% | 20.87% | Upgrade
|
| Enterprise Value | 17,345 | 16,554 | 17,100 | 19,459 | 10,892 | 11,385 | Upgrade
|
| Last Close Price | 30.80 | 30.68 | 30.79 | 34.75 | 15.05 | 14.33 | Upgrade
|
| PE Ratio | 19.50 | 21.18 | 24.72 | 20.05 | 23.09 | 10.68 | Upgrade
|
| Forward PE | - | 28.41 | 28.41 | 28.41 | 28.41 | 28.41 | Upgrade
|
| PS Ratio | 2.53 | 2.61 | 2.86 | 3.65 | 2.17 | 2.24 | Upgrade
|
| PB Ratio | 1.55 | 1.73 | 1.82 | 2.41 | 1.15 | 1.14 | Upgrade
|
| P/TBV Ratio | 1.88 | 2.16 | 2.39 | 3.38 | 1.67 | 1.73 | Upgrade
|
| P/FCF Ratio | 65.78 | 25.61 | 48.24 | 31.98 | 19.39 | 68.14 | Upgrade
|
| P/OCF Ratio | 32.62 | 18.57 | 28.73 | 25.42 | 15.42 | 26.79 | Upgrade
|
| EV/Sales Ratio | 2.84 | 2.98 | 3.33 | 4.44 | 3.37 | 3.75 | Upgrade
|
| EV/EBITDA Ratio | 15.80 | 15.38 | 18.43 | 25.58 | 22.83 | 25.99 | Upgrade
|
| EV/EBIT Ratio | 22.69 | 22.34 | 27.72 | 42.24 | 58.33 | 76.15 | Upgrade
|
| EV/FCF Ratio | 73.88 | 29.24 | 56.09 | 38.84 | 30.10 | 113.85 | Upgrade
|
| Debt / Equity Ratio | 0.28 | 0.30 | 0.30 | 0.51 | 0.57 | 0.62 | Upgrade
|
| Debt / EBITDA Ratio | 2.50 | 2.37 | 2.56 | 4.32 | 7.15 | 8.30 | Upgrade
|
| Debt / FCF Ratio | 11.96 | 4.50 | 7.98 | 6.70 | 9.57 | 37.02 | Upgrade
|
| Net Debt / Equity Ratio | 0.06 | 0.08 | 0.10 | 0.29 | 0.41 | 0.50 | Upgrade
|
| Net Debt / EBITDA Ratio | 0.54 | 0.62 | 0.84 | 2.55 | 5.19 | 6.75 | Upgrade
|
| Net Debt / FCF Ratio | 2.58 | 1.18 | 2.57 | 3.87 | 6.84 | 29.56 | Upgrade
|
| Asset Turnover | 0.47 | 0.46 | 0.45 | 0.41 | 0.31 | 0.32 | Upgrade
|
| Inventory Turnover | 1.75 | 1.83 | 1.99 | 1.97 | 1.59 | 1.74 | Upgrade
|
| Quick Ratio | 1.52 | 1.54 | 1.35 | 1.10 | 0.95 | 0.94 | Upgrade
|
| Current Ratio | 2.45 | 2.42 | 2.14 | 1.73 | 1.64 | 1.91 | Upgrade
|
| Return on Equity (ROE) | 6.03% | 5.68% | 5.49% | 9.71% | 1.93% | 8.82% | Upgrade
|
| Return on Assets (ROA) | 3.76% | 3.85% | 3.36% | 2.68% | 1.13% | 0.98% | Upgrade
|
| Return on Invested Capital (ROIC) | 5.95% | 5.87% | 4.76% | 4.58% | 1.61% | 1.74% | Upgrade
|
| Return on Capital Employed (ROCE) | 6.80% | 7.20% | 6.40% | 5.20% | 2.20% | 1.70% | Upgrade
|
| Earnings Yield | 4.99% | 4.72% | 4.04% | 4.99% | 4.33% | 9.37% | Upgrade
|
| FCF Yield | 1.52% | 3.91% | 2.07% | 3.13% | 5.16% | 1.47% | Upgrade
|
| Dividend Yield | 1.72% | 1.78% | 1.61% | 1.31% | 2.31% | 1.28% | Upgrade
|
| Payout Ratio | 37.93% | 33.41% | 32.69% | 18.60% | 26.32% | 7.16% | Upgrade
|
| Buyback Yield / Dilution | -5.14% | -3.52% | -3.84% | 0.79% | -2.35% | -9.76% | Upgrade
|
| Total Shareholder Return | -3.42% | -1.74% | -2.22% | 2.10% | -0.04% | -8.48% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.